Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

New England Journal of Medicine

Volumn 376, Issue 4, 2017, Pages 305-317

  Wilcox, M H ^a   Gerding, D N ^c,d   Poxton, I R ^b   Kelly, C ^e   Nathan, R ^f   Birch, T ^g   Cornely, O A ⁱ   Rahav, G ^j   Bouza, E ^k   Lee, C ^l   Jenkin, G ^m   Jensen, W ⁿ   Kim, Y S ^o   Yoshida, J ^p   Gabryelski, L ^h   Pedley, A ^h   Eves, K ^h   Tipping, R ^h   Guris, D ^h   Kartsonis, N ^h   Dorr, M B ^h   more..

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d HINES VA HOSPITAL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f Idaho Falls Infectious Disease ^*  (United States)

^g Holy Name Medical Center   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^j SHEBA MEDICAL CENTER   (Israel)

^k UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^l MCMASTER UNIVERSITY   (Canada)

^m SOUTHERN HEALTH   (Australia)

ⁿ Hospital Dr Gustavo Fricke   (Chile)

^o Inje University College of Medicine   (South Korea)

^p Shimonoseki City Hospital   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTOXUMAB; BEZLOTOXUMAB; FIDAXOMICIN; METRONIDAZOLE; PLACEBO; VANCOMYCIN; ANTIINFECTIVE AGENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INFUSION; FATIGUE; FEMALE; FEVER; HEADACHE; HEART DISEASE; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PROCEDURAL SITE REACTION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT INFECTION; SINGLE DRUG DOSE; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; ADOLESCENT; CLINICAL TRIAL; CLOSTRIDIUM INFECTIONS; COMBINATION DRUG THERAPY; INTENTION TO TREAT ANALYSIS; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PEPTOCLOSTRIDIUM DIFFICILE; SECONDARY PREVENTION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; SECONDARY PREVENTION; YOUNG ADULT;

EID: 85011106010     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1602615     Document Type: Article

References (32)

1. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526-36.
2. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370: 1198-208.
3. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012; 55: Suppl 2: S154-S161.
4. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008; 359: 1932-40.
5. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-75.
6. Shields K, Araujo-Castillo RV, Theethira TG, Alonso CD, Kelly CP. Recurrent Clostridium difficile infection: from colonization to cure. Anaerobe 2015; 34: 59-73.
7. Torres JF, Lyerly DM, Hill JE, Monath TP. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun 1995; 63: 4619-27.
8. Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 1998; 66: 2018-25.
9. Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006; 74: 6339-47.
10. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010; 467: 711-3.
11. Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458: 1176-9.
12. Carter GP, Chakravorty A, Pham Nguyen TA, et al. Defining the roles of TcdA and TcdB in localized gastrointestinal disease, systemic organ damage, and the host response during Clostridium difficile infections. MBio 2015; 6(3): e00551.
13. Steele J, Mukherjee J, Parry N, Tzipori S. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis 2013; 207: 323-30.
14. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189-93.
15. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390-7.
16. Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010; 28: 965-9.
17. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197-205.
18. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-4.
19. Fawley WN, Knetsch CW, MacCannell DR, et al. Development and validation of an internationally-standardized, highresolution capillary gel-based electrophoresis PCR-ribotyping protocol for Clostridium difficile. PLoS One 2015; 10(2): e0118150.
20. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372: 825-34.
21. Bauer MP, Notermans DW, van Benthem BHB, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377: 63-73.
22. Morrison RH, Hall NS, Said M, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis 2011; 53: 1173-8.
23. See I, Mu Y, Cohen J, et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 2014; 58: 1394-400.
24. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.
25. Abou Chakra CN, Pepin J, Valiquette L. Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review. PLoS One 2012; 7(1): e30258.
26. Inns T, Gorton R, Berrington A, et al. Effect of ribotype on all-cause mortality following Clostridium difficile infection. J Hosp Infect 2013; 84: 235-41.
27. Rao K, Micic D, Natarajan M, et al. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clin Infect Dis 2015; 61: 233-41.
28. Walker AS, Eyre DW, Wyllie DH, et al. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis 2013; 56: 1589-600.
29. Lim SK, Stuart RL, Mackin KE, et al. Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain. Clin Infect Dis 2014; 58: 1723-30.
30. De Almeida MN, Heffernan H, Dervan A, et al. Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCR-ribotype 244. N Z Med J 2013; 126: 9-14.
31. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012; 55: Suppl 2: S132-S142.
32. Thabit AK, Alam MJ, Khaleduzzaman M, Garey KW, Nicolau DP. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob 2016; 15: 22.